The Taiho and Eli Lilly-backed immunotherapy developer floated in the middle of its range to raise $75.6m, valuing it at about $334m.

Harpoon Therapeutics, a US-based immuno-oncology drug developer that counts pharmaceutical firms Eli Lilly and Taiho as investors, floated on Friday in a $75.6m initial public offering. The offering consisted of 5.4 million shares issued on the Nasdaq Global Select Market and priced at $14 each, in the middle of its $13 to $15 range, valuing…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.